NCT04782622

The Combination of Apatinib and Camerlizumab for Advanced Lung Cancer Patients With Muti-line Therapy

The Combination of Apatinib and Camerlizumab for Advanced Lung Cancer Patients

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 60 (estimated)
• Sponsor: The Affiliated Hospital of Qingdao University · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: —

Summary

The combination of Apatinib and Camrelizumab for progressed NSCLC patients with muti-line therapy : a phaseⅠB clinical study. Brief Summary: Immunotherapy has made a major progress in Lung cancer.However, challenges such as primary and acquired resistance, small fraction of benefit population and lack of predictive and prognostic biomarkers even exist. The overall objective response rate is lower than 20% in second line-treatment and the progression-free survival (PFS) is also similar to or poorer than that of conventional second-line chemotherapy. Apatinib is a novel, orally administered, multitarget receptor tyrosine kinase inhibitor that inhibits VEGFR, PDGFR, FGFR, c-Kit, and other kinases. It functions by inhibiting tumor angiogenesis and proliferative signaling pathways. We would observe and analyze the effectiveness and safety of apatinib combined with Camrelizumab for advanced NSCLC after muti-line therapy to explore the synergistic effect of anti-angiogenic agents and immunotherapy.

Detailed description

Enrolled patients received apatinib plus Camrelizumab treatment (apatinib, 250mg, qd; Camrelizumab, 5mg/kg, iv, d1, 21day as a cycle.)

Conditions

• Lung Cancer

Interventions

Type	Name	Description
DRUG	Apatinib+Camrelizumab	Apatinib 250mg po qd+Camrelizumab 200mg ivdrip q14d

Timeline

• Start date: 2021-03-01
• Primary completion: 2022-01-01
• Completion: 2023-03-01
• First posted: 2021-03-04
• Last updated: 2021-03-04

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study